Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,974 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06356688RecruitingPhase 2
Study of chemo plus immunotherapy before surgery for esophageal cancer
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Nanjing, JiangsuAges 18–75 - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Aurora, ColoradoAges 18 years+ - NCT06363825RecruitingPhase 2
New combination therapy for advanced liver cancer
This trial tests a combination of treatments for advanced liver cancer: a targeted therapy (apatinib), an immunotherapy (camrelizumab), and two local treatments (TAE and HAIC). It may be an option if you have a high tumor burden or a tumor thrombus in the portal vein and haven't had systemic treatment before.
FuzhouAges 18–80 - NCT06380816RecruitingPhase 1/Phase 2
Study of UCB4594 for advanced cancers with HLA-G marker
This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.
LondonAges 18 years+ - NCT06386835Recruiting
Comparing collagen paste to flap surgery for anal fistula
This trial tests a new collagen paste against standard flap surgery for a type of anal fistula. If you've already had a draining seton placed, you may be able to join this study to see which treatment works better.
Shatin, New TerritoriesAges 18 years+ - NCT06390774RecruitingPhase 1
Study of SSGJ-705 for advanced cancers
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
Jinan, ShandongAges 18–75 - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06414317Recruiting
Education tool for advanced bladder cancer patients and caregivers
This study is testing a new educational tool to help people with advanced bladder cancer and their caregivers work together with their care team. It aims to make it easier to stay involved in treatment decisions.
Buffalo, New YorkAges 18 years+ - NCT06415487RecruitingPhase 1
Testing a new cell therapy for advanced EGFR-positive solid tumors
This trial tests a new cell therapy called ACE2016 for people with advanced solid tumors that have EGFR on their surface. It may be an option if you have tried at least two other treatments (including a targeted therapy) and your cancer is still growing.
San Diego, CaliforniaAges 18 years+ - NCT06418659RecruitingEarly Phase 1
CD-801 for advanced liver cancer
This early-phase trial tests an experimental drug called CD-801 given through an IV for people with advanced liver cancer (HCC) that cannot be surgically removed and has not responded to or is not suitable for standard treatments. The goal is to see if CD-801 is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06424665RecruitingPhase 1
Study of FZ-AD005 for advanced solid tumors
This trial tests a new drug called FZ-AD005 for people with advanced solid tumors, especially small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). It may help if standard treatments are no longer working.
Changsha, HunanAges 18–75 - NCT06431269Recruiting
Screening for developmental disorders in children with heart disease
This study is looking for children aged 1 to 5 years who have congenital heart disease and had heart surgery or a procedure in their first year. A special nurse will check for early signs of developmental delays, to see if this kind of screening is helpful for these children.
MontpellierAges 1–5 - NCT06434064RecruitingPhase 2
Tamoxifen and chemotherapy for triple negative breast cancer
This trial tests a combination of tamoxifen (a hormonal therapy) and pegylated liposomal doxorubicin (a type of chemotherapy) for people with triple negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination can help people whose cancer has not responded to at least two prior treatments.
Buffalo, New YorkAges 18 years+ - NCT06434753RecruitingPhase 3
Zinc supplements for stable advanced liver disease
This trial tests whether taking zinc supplements can improve the outlook for people with a certain type of advanced liver disease that is still stable (no major complications). If you have compensated advanced chronic liver disease and meet the criteria, you might be able to join.
BarcelonaAges 18–80 - NCT06449339RecruitingPhase 4
Beta-blocker study for early-stage liver scarring
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hong KongAges 18 years+ - NCT06454383RecruitingPhase 1
Gemcitabine and leflunomide for advanced pancreatic cancer
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
Duarte, CaliforniaAges 18 years+ - NCT06461156RecruitingPhase 1
New targeted drug study for EGFR-mutated lung cancer
This trial tests a new targeted drug (HS-10504) for people with advanced EGFR-mutated non-small cell lung cancer that has worsened after previous EGFR inhibitor therapy. The study aims to see if this drug can help shrink tumors or slow cancer growth.
GuangzhouAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT06472661RecruitingEarly Phase 1
Focused ultrasound plus drug injection for melanoma before surgery
This trial tests a new combination approach for advanced melanoma that is planned for surgical removal. It uses focused ultrasound to heat the tumor, followed by an injection of an experimental immune-stimulating drug (polyICLC), while you continue your standard immunotherapy. The goal is to make the immune system attack the cancer more effectively.
Charlottesville, VirginiaAges 18 years+ - NCT06474468RecruitingPhase 1/Phase 2
Study of a new drug combo for advanced esophageal cancer
This trial tests a combination of two investigational drugs for people with advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if the combination can shrink tumors or slow cancer growth.
Jinan, ShandongAges 18–70 - NCT06484816RecruitingPhase 1
TGRX-1942 study for advanced solid tumor or blood cancer
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
Hangzhou, ZhejiangAges 18 years+ - NCT06484985RecruitingPhase 1
Testing AXT-1003 for advanced blood cancers and solid tumors
This trial tests a new drug (AXT-1003) for people with advanced blood cancers (like non-Hodgkin lymphoma) or solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
BeijingAges 18 years+ - NCT05873686RecruitingPhase 1
Study of NXP900 for advanced solid tumors
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT07178847Recruiting
Cancer DNA after chemoradiation for head and neck cancer
This study looks for cancer DNA left in the body after standard chemoradiation for advanced head and neck squamous cell cancer. It aims to understand if this residual DNA means the disease is more likely to come back.
Aurillac, CANTALAges 18–80
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,974 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.